• 1
    Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178185.
  • 2
    Davidson J, Wilkinson A, Dantal J et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation 2003; 75(10 Suppl): SS3SS24.
  • 3
    Miles AM, Sumrani N, Horowitz R et al. Diabetes mellitus after renal transplantation: As deleterious as non-transplant associated diabetes? Transplantation 1998; 65: 380384.
  • 4
    Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 17351743.
  • 5
    Balkau B, Hu G, Qiao Q, Tuomilehto J, Borch-Johnsen K, Pyorala K, DECODE Study Group; European Diabetes Epidemiology Group. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia 2004; 47: 2118–2128.
  • 6
    Cosio FG, Kudva Y, Van Der Velde M et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005; 67: 24152421.
  • 7
    American Diabetes Association. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26: 520.
  • 8
    World Health Organization. Diabetes. Available at: http://www.who./int/ncd/dia/databases4.htm. Accessed 31 January 2006.
  • 9
    Hoban R, Gielda B, Temkit M et al. Utility of HbA1 c in the detection of subclinical post renal transplant diabetes. Transplantation 2006; 81: 379383.
  • 10
    Hjelmesaeth J, Sagedal S, Hartmann A et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004; 47: 15501556.
  • 11
    Redmon JB, Olson LK, Armstrong MB, Greene MJ, Robertson MP. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 1996; 98: 27862793.
  • 12
    Drachenberg CB, Klassen DK, Weir MR et al. Islet cell damage associated with tacrolimus and cyclosporine: Morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 68: 396402.
  • 13
    Marchetti P, Navalesi R. The metabolic effects of cyclosporin and tacrolimus. J Endocrinol Invest 2000; 23: 482490.
  • 14
    Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis. Am J Transplant 2004; 4: 583595.
  • 15
    Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Br Med J 2005; 331: 810814.
  • 16
    Woodward RS, Schnitzler MA, Baty J et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3: 590598.
  • 17
    Vincenti F, Rostaing L. Rationale and design of the DIRECT study: A comparative assessment of the hyperglycemic effects of tacrolimus and cyclosporine following renal transplantation. Contemp Clin Trials 2005; 26: 1724.
  • 18
    Zucker K, Rosen A, Tsaroucha A et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transplant Immunol 1997; 5: 225232.
  • 19
    Van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 119128.
  • 20
    Pou L, Brunet M, Cantarell C et al. Mycophenolic acid plasma concentrations: Influence of comedication. Ther Drug Monit 2001; 23: 3538.
  • 21
    Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713723.
  • 22
    Stumvoll M, Mitrakou A, Pimenta W et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000; 23: 295301.
  • 23
    Hjelmesaeth J, Midtvedt K, Jenssen T, Hartmann A. Insulin resistance after renal transplantation: Impact of immunosuppressive and antihypertensive therapy. Diabetes Care 2001; 24: 21212126.
  • 24
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.
  • 25
    Bauer P, Rohmel J, Maurer W, Hothorn L. Testing strategies in multi-dose experiments including active control. Stat Med 1998; 17: 21332146.
  • 26
    The European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal Products (CPMP). Points to consider on multiplicity issues in clinical trials, London (2002)
  • 27
    Van Duijnhoven EM, Boots JM, Christiaans MH, Van Hooff JP. Metabolic aspects of tacrolimus in renal transplantation. Consequences for the choice of an immunosuppressive regimen and for the management of post-transplant diabetes mellitus. Minerva Urol Nefrol 2003; 55: 3342.
  • 28
    Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease—Major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60: 451457.
  • 29
    Jardine A. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine. Transplant Int 2005; 18: 379384.
  • 30
    Margreiter R for the European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: A randomised multicentre study. Lancet 2002; 359: 741746.
  • 31
    Levy G, Villamil F, Samuel D et al. Results of LIS2 T, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004; 77: 16321638.
  • 32
    Wilkinson A, Davison J, Dotta F et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005; 19: 291298.
  • 33
    Kaplan B, Meier-Kriesche H-U, Minnik P et al. Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. Clin Transplant 2005; 19: 551558.